Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Sei Investments Co.

Sei Investments Co. trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 38.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,164 shares of the company’s stock after selling 13,085 shares during the quarter. Sei Investments Co. owned 0.07% of Krystal Biotech worth $3,316,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the 3rd quarter worth $40,000. Avanza Fonder AB purchased a new stake in Krystal Biotech during the fourth quarter worth about $119,000. KBC Group NV grew its position in Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after buying an additional 297 shares during the period. Blue Trust Inc. raised its holdings in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares during the last quarter. Finally, US Bancorp DE grew its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. Finally, Chardan Capital boosted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $220.00.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Trading Down 1.6 %

Shares of KRYS opened at $178.13 on Friday. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of 59.58 and a beta of 0.75. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The stock has a 50 day moving average of $172.94 and a 200-day moving average of $173.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis. During the same quarter last year, the company posted $0.30 earnings per share. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).